Royal Bank of Canada reissued their hold rating on shares of Novelion Therapeutics (NASDAQ:NVLN) (TSE:QLT) in a report released on Friday. They currently have a $7.00 price target on the biotechnology company’s stock.
NVLN has been the topic of several other reports. Zacks Investment Research cut shares of Novelion Therapeutics from a hold rating to a sell rating in a research note on Friday, November 17th. ValuEngine cut shares of Novelion Therapeutics from a sell rating to a strong sell rating in a research note on Thursday, March 1st.
Shares of Novelion Therapeutics (NASDAQ:NVLN) traded up $0.02 on Friday, reaching $4.54. 51,532 shares of the company’s stock traded hands, compared to its average volume of 21,467. The company has a quick ratio of 1.28, a current ratio of 1.45 and a debt-to-equity ratio of 6.53. The firm has a market cap of $84.31, a PE ratio of -0.67 and a beta of 0.84. Novelion Therapeutics has a 12 month low of $3.08 and a 12 month high of $11.29.
WARNING: This piece was originally published by StockNewsTimes and is owned by of StockNewsTimes. If you are accessing this piece on another site, it was illegally stolen and republished in violation of U.S. and international trademark and copyright legislation. The correct version of this piece can be read at https://stocknewstimes.com/2018/03/17/novelion-therapeutics-nvln-receives-hold-rating-from-royal-bank-of-canada.html.
Novelion Therapeutics Company Profile
Novelion Therapeutics Inc, formerly QLT Inc, is a Canada-based biopharmaceutical company. The Company is engaged in development of new standards of care for individuals living with rare diseases. The Company is focused on advancing its portfolio of rare disease therapies by investing in science and clinical development.
Receive News & Ratings for Novelion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novelion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.